IL138615A0 - Alphaviral gene expression system and dna molecules for use therein - Google Patents

Alphaviral gene expression system and dna molecules for use therein

Info

Publication number
IL138615A0
IL138615A0 IL13861599A IL13861599A IL138615A0 IL 138615 A0 IL138615 A0 IL 138615A0 IL 13861599 A IL13861599 A IL 13861599A IL 13861599 A IL13861599 A IL 13861599A IL 138615 A0 IL138615 A0 IL 138615A0
Authority
IL
Israel
Prior art keywords
rna molecules
gene expression
untranslated
methods
expression system
Prior art date
Application number
IL13861599A
Other languages
English (en)
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of IL138615A0 publication Critical patent/IL138615A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL13861599A 1998-03-27 1999-03-25 Alphaviral gene expression system and dna molecules for use therein IL138615A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7956298P 1998-03-27 1998-03-27
PCT/IB1999/000523 WO1999050432A1 (fr) 1998-03-27 1999-03-25 Systeme d'expression des genes d'alphavirus a induction

Publications (1)

Publication Number Publication Date
IL138615A0 true IL138615A0 (en) 2001-10-31

Family

ID=22151327

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13861599A IL138615A0 (en) 1998-03-27 1999-03-25 Alphaviral gene expression system and dna molecules for use therein

Country Status (10)

Country Link
US (2) US7005275B2 (fr)
EP (1) EP1066395B1 (fr)
JP (2) JP2002509729A (fr)
AT (1) ATE304603T1 (fr)
AU (1) AU757549B2 (fr)
CA (1) CA2325564A1 (fr)
DE (2) DE69927249T2 (fr)
IL (1) IL138615A0 (fr)
NZ (1) NZ507195A (fr)
WO (1) WO1999050432A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2325564A1 (fr) * 1998-03-27 1999-10-07 Cytos Biotechnology Ag Systeme d'expression des genes d'alphavirus a induction
US7241617B2 (en) * 1998-07-03 2007-07-10 Dnavec Research, Inc. Sendai viral vectors comprising foreign genes inserted between the R1 and R2 Loci
ES2326101T3 (es) * 1998-07-03 2009-09-30 Dnavec Research Inc. Vector de virus arn cadena (-) para celulas nerviosas.
JP2002521461A (ja) * 1998-07-29 2002-07-16 インビトロゲン・コーポレーション Ｒｎａウイルスを用いる組換えタンパク質の調節発現
AU7938900A (en) * 1999-10-27 2001-05-08 Cytos Biotechnology Ag Method for creating divergent populations of nucleic acid molecules and proteins
WO2001042442A2 (fr) * 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation de genes endogenes basee sur un replicon
WO2001085208A2 (fr) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Jeu ordonne d'antigenes moleculaires
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
CA2460269C (fr) * 2001-09-06 2013-01-15 Alphavax, Inc. Systemes de vecteurs a base de replicons alphaviraux
US20060251620A1 (en) * 2002-08-22 2006-11-09 Lidia Ivanova Inducible alphaviral/orip based gene expression system
EP1644508A1 (fr) 2003-07-11 2006-04-12 Cytos Biotechnology AG Systeme d'expression genetique
US20080096274A1 (en) * 2006-10-24 2008-04-24 Guangpu Li Recombinant alphavirus vectors and methods of using same
WO2016209989A1 (fr) * 2015-06-26 2016-12-29 The Regents Of The University Of California Procédé d'identification de promoteurs d'arn
US9859156B2 (en) * 2015-12-30 2018-01-02 Taiwan Semiconductor Manufacturing Co., Ltd. Interconnection structure with sidewall dielectric protection layer
GB201603374D0 (en) 2016-02-26 2016-04-13 Ucl Business Plc Packaging cell
CA3162690A1 (fr) * 2019-12-31 2021-07-08 Minoru S. H. Ko Administration transitoire basee sur la temperature d'acides nucleiques et de proteines a des cellules et des tissus
WO2023034881A1 (fr) * 2021-09-02 2023-03-09 Elixirgen Therapeutics, Inc. Immunothérapie à base d'arn à température pouvant être régulée pour le cancer
CN113846113B (zh) * 2021-09-09 2022-09-13 臻赫医药(杭州)有限公司 一种有限自我复制mRNA分子系统、制备方法及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5458878A (en) * 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
WO1994017813A1 (fr) 1993-02-08 1994-08-18 Paravax, Inc. VECTEURS DU VIRUS SINDBIS DEFECTIF QUI EXPRIMENT DES ANTIGENES P30 $i(TOXOPLASMA GONDII)
ATE440957T1 (de) 1993-09-15 2009-09-15 Novartis Vaccines & Diagnostic Rekombinante alphavirus vektoren
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5532154A (en) * 1994-03-21 1996-07-02 Research Development Foundation Mutated alpha virus
WO1996017072A2 (fr) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Vecteurs d'alphavirus de recombinaison
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
ATE386811T1 (de) 1996-04-05 2008-03-15 Novartis Vaccines & Diagnostic Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
CA2325564A1 (fr) * 1998-03-27 1999-10-07 Cytos Biotechnology Ag Systeme d'expression des genes d'alphavirus a induction

Also Published As

Publication number Publication date
CA2325564A1 (fr) 1999-10-07
WO1999050432A1 (fr) 1999-10-07
JP2002509729A (ja) 2002-04-02
EP1066395A1 (fr) 2001-01-10
JP2005323620A (ja) 2005-11-24
US20060024788A1 (en) 2006-02-02
NZ507195A (en) 2003-07-25
ATE304603T1 (de) 2005-09-15
US7005275B2 (en) 2006-02-28
DE69927249T2 (de) 2006-06-29
US20030053988A1 (en) 2003-03-20
DE69927249D1 (de) 2005-10-20
DE1066395T1 (de) 2002-04-04
AU757549B2 (en) 2003-02-27
AU2848199A (en) 1999-10-18
EP1066395B1 (fr) 2005-09-14

Similar Documents

Publication Publication Date Title
IL138615A0 (en) Alphaviral gene expression system and dna molecules for use therein
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
Paterson et al. Efficient translation of prokaryotic mRNAs in a eukaryotic cell-free system requires addition of a cap structure
JP6284181B2 (ja) 環状ｒｎａ及びタンパク質の製造方法
Wengler et al. Identification of a transfer of viral core protein to cellular ribosomes during the early stages of alphavirus infection
BR0010725A (pt) Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
BRPI0511118A (pt) polipeptìdeos de haemophilus influenzae não transcritos
Nass Modified nucleosides and cancer
HUP9800329A2 (hu) Nukleinsavkonstrukciók strukturális gének sejtciklus-függő módon szabályozott expresszálására
EP0232523A3 (en) Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
Smolar et al. DNA sequences of polyoma virus early deletion mutants
JPS5978692A (ja) バクテリオフア−ジからバクテリアを保護する方法
HUP0302481A2 (hu) Virulencia gének, fehérjék és alkalmazásuk
US20200362382A1 (en) Methods of preparing modified rna
Carlson et al. 1-Methylguanosine in place of Y base at position 37 in phenylalanine tRNA is responsible for its shiftiness in retroviral ribosomal frameshifting
SE0102204D0 (sv) New method
HUP0304053A2 (hu) Új expressziós vektorok és azok alkalmazása
CO5650177A2 (es) Constructos geneticos y composiciones que comprenden rre y cte y usos de estos
AUPM772494A0 (en) Improvements in production of proteins in host cells
ATE332971T1 (de) Typ ii dns polymerase aus pyrococcus abyssi
Oppermann et al. Isolation and structure of repressor-like proteins from the archaeon Sulfolobus solfataricus: Co-purification of RNase A with Sso7c
Erhan Model for DNA Polymerase
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen
AU5076393A (en) Proteins which regulate the expression of vertebrate MHC class II genes, DNA sequences encoding them and pharmaceutical compositions
Davern et al. Nucleic acids and proteins